U.S. markets open in 4 hours 15 minutes

Xencor, Inc. (XNCR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.17+2.96 (+7.36%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close40.21
Open40.12
Bid43.00 x 800
Ask0.00 x 800
Day's Range40.12 - 43.48
52 Week Range26.80 - 58.35
Volume283,042
Avg. Volume233,300
Market Cap2.501B
Beta (5Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-1.21
Earnings DateMay 05, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Xencor Presents Positive Data For XmAb Antibodies Program Against Cancer
    SmarterAnalyst

    Xencor Presents Positive Data For XmAb Antibodies Program Against Cancer

    Xencor presented new data from multiple preclinical studies for XmAb bispecific antibody and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting. Xencor’s (XNCR) IL-12-Fc cytokine program is based on the clinical-stage biopharma company’s earlier work with IL-15-Fc cytokines in oncology, where the reduction in potency led to improved pharmacodynamics (PD) , pharmacokinetics (PK) and tolerability in preclinical studies. Xencor’s John Desjarlais, Ph.D., senior vice president and chief scientific officer said, “Xencor’s XmAb bispecific Fc domains enable the rapid design and simplified development of Fc-containing protein structures and are being used to create new platforms, a wide range of multi-specific antibodies and engineered cytokines.” “In 2021, we anticipate submitting an IND [investigational new drug] for XmAb819, our lead XmAb 2+1 CD3 bispecific antibody targeting ENPP3, and initiating a Phase 1 study in early 2022. We are also advancing through preclinical development our wholly owned lead CD28 candidate, a B7-H3 x CD28 bispecific antibody designed to be evaluated for the treatment of patients with a range of solid tumors,” Desjarlais added. L-12 is a protein that stimulates the immune system and is produced by activated antigen-presenting cells leading to a rise in T cells and natural killer (NK) cells and an increase in cytotoxicity through high levels of interferon-gamma signaling. The lesser potency in the IL-12-Fc preclinical study indicated “significant anti-tumor activity in vivo [inside the body] concurrent with activation and proliferation of CD8+ T cells and increased levels of interferon gamma in serum.” The company’s PD-L1 x CD28 bispecific antibodies stimulate T-cells, a type of immune cells in the body and activate them when bound to tumor cells. PD-L1 is a protein that is expressed on different kinds of tumors and suppresses responses by the immune system against the tumor. (See Xencor Inc stock analysis on TipRanks) Following the preclinical data presentation, Mizuho Securities analyst Mara Goldstein reiterated a Buy with a price target of $57 on the stock. Goldstein said, “The presentations highlight the broad utility of XNCR’s XmAb antibody engineering platform for exploring novel mechanisms and paradigms in cancer immunotherapy. “ “XNCR is advancing candidates in clinical trials, and we see the transition to a broader therapeutic-driven valuation as evolving with data. Ultimately new candidates that demonstrate the breadth of the company’s technology could offer additional optionality that drives value expansion,” Goldstein added. Overall, the rest of the Street is cautiously optimistic on the stock with a Moderate Buy consensus rating based on 5 Buys and 1 Sell. The average analyst price target of $53 implies that XNCR shares have approximately 34.2% upside potential to current levels. Related News: Iovance Gives Clinical Data Update For Melanoma Drug Sanofi Snaps Up Tidal Therapeutics For $160M Sorrento’s Subsidiary Scilex Gets FDA Nod For ZTlido Label Expansion More recent articles from Smarter Analyst: Wall Street Roundup: Bullish & Bearish Calls Of The Day Sorrento’s Subsidiary Scilex Gets FDA Nod For ZTlido Label Expansion McGrath RentCorp Snaps Up Facility Rental Company Kitchens To Go Alnylam Reports Positive Interim Results From Phase 1 Study Of ALN-AGT

  • Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
    Business Wire

    Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.

  • Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
    GlobeNewswire

    Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies

    Lead product candidate, ZB001, has first-in-class potential in China for Thyroid Eye Disease Rapidly advancing seven pipeline programs, including three worldwide, with best-in-class potential in autoimmune and rare diseases Expanding a proven leadership team of veteran life science industry executives Company founded and initially funded by Tellus BioVentures and Fairmount HONG KONG and BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Zenas BioPharma (“Zenas”) launched today as a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world. Zenas was founded and initially funded by Tellus BioVentures, LLC (“Tellus”) and Fairmount Funds Management LLC (“Fairmount”) and is additionally backed by a syndicate of leading global life science investment funds including Quan Capital, WuXi Biologics Healthcare Ventures and Wellington Management. Lonnie Moulder, Managing Member of Tellus and Founder of Zenas, serves as Executive Chairman and Interim Chief Executive Officer. As a veteran life sciences founder and executive, he brings to Zenas a track record of success and the necessary skills to navigate the global biopharmaceutical landscape. Mr. Moulder has assembled an experienced leadership team with strong credentials in acquiring, developing and commercializing products across the globe. “We are excited about the launch of Zenas BioPharma and its pipeline of differentiated product candidates. These potentially best-in-class products are intended to bring innovation to patients with underserved diagnoses while also maximizing value across the healthcare ecosystem,” said Mr. Moulder. “The expanding Zenas leadership team and our network of business partners will drive operational excellence to deliver potentially transformative therapies to improve the lives of people living with autoimmune and rare diseases.” “We are thrilled to invest in and support this new venture lead by a proven and experienced team,” added Marietta Wu, MD, Ph.D., MBA, Managing Director at Quan Capital and Zenas Board Member. “Immunology is an area of transformative innovation poised to solve great unmet medical needs. We are confident that by leveraging cross border research and development capabilities and resources, Zenas will rapidly advance its current portfolio and establish its global leadership with an expanded pipeline coupled with a strong footprint in China.” Rapidly Advancing Pipeline Zenas debuts with a deep pipeline of seven innovative immune-based therapeutics that will continue to expand through a successful business development strategy. Zenas owns worldwide rights to three of the seven pipeline programs, which uniquely positions the Company to be global in scope. Zenas innovation is defined by the selection of product candidates that are designed with best-in-class potential and then advanced utilizing differentiated development and commercial strategies to address patient needs AND the value requirements of the dynamic healthcare environment. Zenas innovation further includes acquiring or discovering first-in-class product candidates based upon new knowledge in the evolving field of immunology. ZB001 and ZB011 Zenas is developing its lead product candidate ZB001, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (mAb), for the potential treatment of patients in China with thyroid eye disease (TED). TED is a debilitating condition that significantly impacts quality of life and can cause proptosis (“bulging eyes”), double vision and vision loss. ZB001, a potential first-in-class product in China, was exclusively in-licensed from Viridian Therapeutics, Inc. (“Viridian”) (NASDAQ: VRDN). More than 100 oncology patients have previously been treated with the antibody in US and EU studies, under the name AVE-1642, enabling understanding of its pharmacokinetic and pharmacodynamic profile, as well as its safety and tolerability. Viridian maintains all rights outside of China and is developing the IGF1R mAb under the name VRDN-001. This program is advancing rapidly with an expected Investigational New Drug (“IND”) application filing by Viridian in late 2021, followed by a Zenas filing in China. Data from the first clinical trial involving patients is expected to be available in 2022. In parallel with ZB001 development, Viridian and Zenas initiated the ZB011 program, which seeks to improve IGF1R-targeted antibodies to further enhance dosing and convenience. ZB002, ZB003 and ZB004 The Zenas pipeline also includes three potentially best-in-class mAbs (ZB002, ZB003, ZB004) exclusively in-licensed worldwide from Xencor, Inc. (NASDAQ: XNCR). These three mAbs were engineered with XmAb™ technology for improved potency, half-life, and stability and are undergoing IND-enabling studies to support clinical development for both new and established autoimmune disease indications. ZB005 and ZB006 Zenas additionally entered a collaboration with Dianthus Therapeutics, Inc. (“Dianthus”) that provides China rights for two mAb programs, ZB005 and ZB006. Dianthus is a privately held biotechnology company focused on the discovery and development of monoclonal antibody therapeutics that modulate the immune complement system for the treatment of autoimmune diseases. IND-enabling activities are underway for ZB005, the first of the two programs. About Zenas BioPharma Zenas BioPharma is a cross-border (China-USA based) biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn. Contacts Investor Contact: Zenas BioPharmaIR@zenasbio.com Media Contact: Lauren BartlettZenas BioPharmalauren.bartlett@zenasbio.com